|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002003,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0027740,
umls-concept:C0027788,
umls-concept:C0034693,
umls-concept:C0034721,
umls-concept:C0038879,
umls-concept:C0071716,
umls-concept:C0443252,
umls-concept:C1280500,
umls-concept:C1456501
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1990-6-6
|
|
pubmed:abstractText |
To test the hypothesis that aldose reductase inhibition may prevent or delay the development of functional and structural neuropathy in the insulin-deficient diabetic Bio-Breeding rat (BB-rat), hyperglycemic rats were begun on the aldose reductase inhibitor (ARI) ponalrestat 25 mg/kg body wt soon after the onset of diabetes and followed for 4 or 6 mo. Ponalrestat treatment completely prevented the characteristic nerve conduction slowing and structural abnormalities of the node of Ranvier for 4 mo despite only partial preservation of axonal integrity. Ponalrestat treatment for 6 mo achieved a partial but significant prevention of nerve conduction slowing, axoglial dysjunction, and axonal degenerative changes. This incomplete but significant prevention of neuropathy by ponalrestat suggests that additional mechanisms besides polyol-pathway activation may be of importance in the pathogenesis of diabetic neuropathy. Alternatively, the dosage used in the present study may not have been sufficient to achieve a complete prevention. Despite the only partial protective effect of ARI treatment on degenerative peripheral nerve changes in hyperglycemic BB-rats, 6 mo of treatment resulted in a more than threefold increase in regenerating nerve fibers. These data suggest that prophylactic ARI treatment may be efficacious in delaying the development of diabetic neuropathy.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-124320,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-2412918,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-2438993,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-2451191,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-2536048,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-2537578,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-2752883,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-2838351,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-2968441,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-2988888,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-3003160,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-3026877,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-3027558,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-3033025,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-3136330,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-3136331,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-3326819,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-3339124,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-3367221,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-3898998,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-3930330,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-4058670,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-4100402,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-5581540,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-6093549,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-6182509,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-6202576,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-6401351,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-6847138,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-6848907,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-6959136,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-6991317,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-7301046,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2110189-7348034
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0021-9738
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
85
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1410-20
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:2110189-Aldehyde Reductase,
pubmed-meshheading:2110189-Animals,
pubmed-meshheading:2110189-Axons,
pubmed-meshheading:2110189-Blood Glucose,
pubmed-meshheading:2110189-Diabetes Mellitus, Experimental,
pubmed-meshheading:2110189-Diabetic Neuropathies,
pubmed-meshheading:2110189-Hemoglobin A, Glycosylated,
pubmed-meshheading:2110189-Male,
pubmed-meshheading:2110189-Microscopy, Electron,
pubmed-meshheading:2110189-Motor Neurons,
pubmed-meshheading:2110189-Nerve Fibers, Myelinated,
pubmed-meshheading:2110189-Neural Conduction,
pubmed-meshheading:2110189-Phthalazines,
pubmed-meshheading:2110189-Prediabetic State,
pubmed-meshheading:2110189-Pyridazines,
pubmed-meshheading:2110189-Ranvier's Nodes,
pubmed-meshheading:2110189-Rats,
pubmed-meshheading:2110189-Rats, Inbred BB,
pubmed-meshheading:2110189-Reference Values,
pubmed-meshheading:2110189-Spinal Nerves,
pubmed-meshheading:2110189-Sugar Alcohol Dehydrogenases,
pubmed-meshheading:2110189-Sural Nerve
|
|
pubmed:year |
1990
|
|
pubmed:articleTitle |
Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.
|
|
pubmed:affiliation |
Department of Pathology, University of Manitoba, Winnipeg, Canada.
|
